Sex: M
Vaccine: MEN
Symptoms: Meningococcal infection, Urethritis gonococcal
Clinical narrative: Neisseria meningitidis; Urethral gonorrhea infection; This case was reported in a literature article and described the occurrence of neisseria meningitidis infection nos in a male patient who received Men B NVS (Meningococcal B vaccine) for prophylaxis.  On an unknown date, the patient received Meningococcal B vaccine at an unknown dose. On an unknown date, unknown after receiving Meningococcal B vaccine, the patient experienced neisseria meningitidis infection nos (serious criteria GSK medically significant) and urethritis gonococcal. On an unknown date, the outcome of the neisseria meningitidis infection nos and urethritis gonococcal were unknown.   It was unknown if the reporter considered the neisseria meningitidis infection nos and urethritis gonococcal to be related to Meningococcal B vaccine.  Additional details were provided as follows: This case was reported in a literature article and described the occurrence of urethral gonorrhea infection in a male patient of unspecified age who was vaccinated with unspecified meningococcal B vaccine (Unknown manufacturer) for prophylaxis. The patient was part of dataset constructed by combining surveillance and medical record data from men diagnosed with uropathogenic, non-groupable Neisseria meningitidis (NmNG) clade urethritis in a local sexually transmitted disease (STD) clinic. Time-to-event analyses of clinic visits between January 2015 and April 2018 was used to examine prospective urethral gonorrhea risk. In this study, subsequent gonorrhea acquisition for men with NmNG clade urethritis at baseline was compared to men with Neisseria gonorrhea (Ng) urethritis (n=255), chlamydial urethritis (n=253), or no infection (n=257) at baseline. [In this study, participants were primarily Black and heterosexual with a median age of 28 years. At baseline, 13% had prior gonorrhea history]. No information on patient's medical or family history or concurrent condition or concomitant medication was provided. On an unspecified date, the patient received unspecified meningococcal B vaccine (administration route and site unspecified, dosage unknown; batch number not provided). The age of vaccination was not provided.  On an unspecified date, an unknown period after vaccination, the patient was diagnosed with uropathogenic, non-groupable Neisseria meningitidis (NmNG) clade urethritis in a local STD clinic. Subsequently, on an unspecified date between January 2015 and April 2018, the patient developed urethral gonorrhea infection.  Treatment was unknown. The outcome of the event was not provided. [In this study, half of men returned for STD screening at least once during the follow-up period.] The author did not comment on the relationship between the event of urethral gonorrhea infection and unspecified meningococcal B vaccine. The authors stated, "Men with NmNG clade urethritis at baseline had similar gonorrhea risk as men with Ng at baseline. Results were not meaningfully different when assessing extragenital gonococcal infections, or after adjustment for time since baseline, age, race, sexual orientation, prior gonorrhea infection, and sexual behavior (number of partners, condom use, and oral sex). In contrast, those with NmNG clade urethritis had increased gonorrhea incidence compared to men with chlamydial urethritis and men with no infection at baseline." The authors concluded "Natural infection with NmNG urethritis clade does not appear to protect men against subsequent acquisition of gonorrhea".      Lab Comments: On an unspecified date between January 2015 and April 2018, the patient was diagnosed with NmNG clade urethritis in a local STD clinic.